Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171092 · ClinicalTrials.gov registry record · Early Phase 1
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
A Early Phase 1 study of Malignant Lymphoma, Stem Cell Type and Autologous Transplant, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT01171092: Completed Early Phase 1 study of Malignant Lymphoma, Stem Cell Type and Autologous Transplant, sponsored by University of Kansas Medical Center.
NCT01171092 is a Early Phase 1 study of Malignant Lymphoma, Stem Cell Type and Autologous Transplant that has completed, run by University of Kansas Medical Center. The registered enrollment target is 21 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01171092, a Early Phase 1 study of Malignant Lymphoma, Stem Cell Type and Autologous Transplant, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization.
Primary Outcome
The primary aim of this single-arm pilot study is to determine the effectiveness of a combination of Bortezomib and G-SCSF in blood stem cell mobilization through the estimation of the proportion of patients receiving treatment that obtain adequate stem cell yield.
Conditions Studied
Interventions
- DRUG bortezomib and G-CSF
Study Locations (2)
Kansas
- University of Kansas Medical Center - Kansas City
- University of Kansas Medical Center, Westwood Campus - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
What the finished NCT01171092 record still lists
NCT01171092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Malignant Lymphoma, Stem Cell Type appearing as the primary indexed condition, and to 1 intervention - of which bortezomib and G-CSF is the first listed.
NCT01171092 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01171092 about?
NCT01171092 is a clinical study titled "A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma". The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization.
What is the current status of trial NCT01171092?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2010-09. Estimated completion is 2014-12.
What conditions does trial NCT01171092 study?
This clinical trial studies the following conditions: Malignant Lymphoma, Stem Cell Type, Autologous Transplant.
What interventions are being tested in trial NCT01171092?
The interventions under investigation include: bortezomib and G-CSF (DRUG).
Who is sponsoring clinical trial NCT01171092?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01171092 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01171092's enrollment target sits among peer trials
21 1130th of 2000 higher than 845 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia